We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Bevacizumab nasal spray: Noninvasive treatment of epistaxis in patients with rendu-osler disease.
- Authors
Guldmann, Romain; Dupret, Agnes; Nivoix, Yasmine; Schultz, Philippe; Debry, Christian
- Abstract
Objectives/Hypothesis: To evaluate the efficacy and safety of bevacizumab administered at a concentration of 50 mg as an intranasal spray in the treatment of epistaxis in patients suffering from Rendu-Osler disease. Study Design: Prospective. Methods: A preliminary, prospective, review board-approved study was conducted on six patients with Rendu-Osler disease who received 10 treatment courses of 50 mg bevacizumab. Monthly follow-up was based on the epistaxis severity score (ESS), with adverse effects being reported. Results: Ten treatment courses were administered to six patients, with a mean follow-up period of 2.8 months. A statistically significant decrease in mean ESS was observed at 1 month ( P < .001) and 2 months ( P < .005), whereas a nonsignificant decrease was found at 3 months ( P = .07). A nonsignificant decline in mean ESS was detected at 1 month in patients with ESS ≥7 at baseline. No adverse effects were reported. Conclusions: The intranasal spray application of 50 mg bevacizumab was found to be an effective symptomatic treatment over a period of 2 months for patients with a pretreatment ESS of <7, with no adverse effects being noted.
- Subjects
BEVACIZUMAB; INTRANASAL medication; NOSEBLEED treatment; NONINVASIVE diagnostic tests; CARDIOVASCULAR system abnormalities
- Publication
Laryngoscope, 2012, Vol 122, Issue 5, p953
- ISSN
0023-852X
- Publication type
Article
- DOI
10.1002/lary.23230